pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

Science Corp's retinal implant gains European approval, eyesight aid for macular degeneration patients

Jul 22, 2026·read at STAT ↗ApprovalPositive

Science Corporation announced that European regulators have approved its retinal implant for patients with age-related macular degeneration.

The device, described as a 'cochlear implant for vision', is intended to improve central vision enough for reading and recognizing road signs.

The company says the product is now available commercially in Europe and expects to seek U.S. launch around 2027.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027”

read at STAT ↗
436 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.3
drugs
Rare Disease3
topics
Ophthalmology6AMD3Rare Disease3Psychiatry & CNS2

related stories

  • Jul 30Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemptionSTAT
  • Jul 27FDA scientists question Capricor data; Legend CEO steps downBioPharma Dive
  • Jul 22Webinar: From Clinical to Commercial: Talent Strategies for Biopharma GrowthBioSpace
  • Jul 18‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive